Guillain–Barré Syndrome Market - Snapshot
The global Guillain–Barré syndrome market is expanding at a moderate pace, due to increase in the prevalence of Guillain–Barré syndrome across the globe and increasing use of IVIG in off-label indications. The global Guillain–Barré syndrome market was valued at US$ 454.0 Mn in 2016 and is projected to register a compounded annual growth rate (CAGR) of over 5% from 2017 to 2025 to reach value of US$ 708.6 Mn by 2025.
Intravenous immunoglobulins (IVIG) are used for the treatment of Guillain–Barré syndrome. IVIG products such as Gamunex, Gammagard/Kiovig, and Privigen are given in the dose of 0.4 g/kg of body weight per day for five days. Plasma exchange is a proven treatment for Guillain–Barré syndrome. Other treatments such as analgesics, anticonvulsants, and low-molecular-weight heparin are employed to alleviate symptoms and post-treatment complications of Guillain–Barré syndrome. Key driving factors for the market include increase in the incidence of Guillain-Barre syndrome, rise in usage of IVIG in off-label indications, and improved technology for production and purification methods. The number of patients reported with Guillain-Barre syndrome has increased in the last few years. Infection caused by bacterium Campylobacter jejuni is considered to be one of the most common risk factors for developing Guillain-Barre syndrome. The syndrome can also develop after acquiring flu or infection of Cytomegalovirus or Epstein–Barr virus. Guillain-Barre syndrome may develop in the days or weeks following vaccination. According to the Centers for Disease Control & Prevention (CDC), the geriatric population is at a higher risk of developing Guillain-Barre syndrome (GBS), as the incidence of the syndrome increases with age. People aged over 50 years are at the highest risk of developing GBS. Every year, around 3,000 to 6,000 people in the U.S. acquire GBS, whether or not they had received vaccination. The incidence rate is 1 to 2 individuals out of every 100,000 people.
In terms of therapeutics, the market for Guillain-Barre syndrome has been segmented broadly into intravenous immunoglobulin, plasma exchange, and others (analgesics, anticonvulsants, LMWH, etc.). Based on route of administration, the market has been segmented into oral and parenteral. Based on distribution channel, the Guillain-Barre syndrome market has been divided into hospital pharmacies, retail pharmacies, and others (home care, clinics, etc.). Hospital pharmacies is the rapidly expanding segment, owing to increasing incidence of GBS and significant adoption of newer treatments.
Among therapeutics, the intravenous immunoglobulins segment held the largest market share. Intravenous immunoglobulin (IVIG) is a treatment wherein antibodies from donated blood are injected into the patient's vein. IVIG is extensively used due to its ease of administration and favorable side-effect profile. IVIG is administered in doses of 0.4g/kg of body weight per day for 5 days. Unmet needs for management of Guillain-Barre syndrome and promising pipeline of novel molecules and their approval are major factors that are estimated to drive the IVIG segment during the forecast period. Guillain-Barre syndrome is a rare disease. Rare diseases cause a significant financial and medical burden on patients, health care systems, and medical fraternity. Extensive research programs in the field of renal treatment have resulted in several new drugs being developed and approved every year.
Based on geography, the global Guillain-Barre syndrome market has been divided into five major regions: North America, Europe, Asia, Latin America, and Middle East & Africa. North America and Europe hold the leading share of the global Guillain-Barre syndrome market, followed by Asia Pacific, Latin America, and Middle East & Africa. The U.S. dominates the Guillain-Barre syndrome market in North America. This is majorly due to factors such as high cost of therapeutic products and high awareness among end-users. Also, the market in the U.S. is driven by increased adoption of newly introduced therapeutic drugs and availability of insurance plans for costly treatment of rare diseases in the country. Europe is the second-largest market for Guillain-Barre syndrome. Germany is a major contributor to the Guillain-Barre syndrome market in Europe. The Guillain-Barre syndrome market in Asia Pacific is expanding rapidly, primarily due to presence of developing countries in the region. Growing awareness about rare diseases and expenditure on health care in the region drive the Guillain-Barre syndrome market in Asia Pacific. On the other hand, less penetration of healthcare facilities and lack of availability of products for the treatment of Guillain-Barre syndrome restrain the Guillain-Barre syndrome market in regions such as Latin America and Middle East & Africa.
Key players operating in the global Guillain-Barre syndrome market are Grifols S.A., CSL Behring LLC, Shire plc, Octapharma AG, Nihon Pharmaceutical Co., Ltd., Akari Therapeutics, PLC, China Biologic Products Holdings, Inc., Biotest AG, and Kedrion s.p.A.
The global Guillain–Barré syndrome market has been segmented as follows:
|
Therapeutics |
|
|
Route of Administration |
|
|
Distribution Channel |
|
|
Geography |
|
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology
3. Executive Summary
3.1. Global Guillain–Barré Syndrome Market Size (US$ Mn) and Distribution, by Geography, 2017 and 2025
3.2. Global Guillain–Barré Syndrome Market Snapshot, 2016
3.3. Global Guillain–Barré Syndrome Market: Opportunity Map
4. Market Overview
4.1. Overview
4.2. Global Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, 2015–2025
4.3. Global Guillain–Barré Syndrome Market Outlook
4.4. Global Guillain–Barré Syndrome Market: Key Market Developments
4.5. Global Guillain–Barré Syndrome Market: Porter’s Five Forces
4.6. Global Guillain–Barré Syndrome Market: Key Success Factors of Top 3 Players
4.7. Guillain–Barré Syndrome: Disease Overview
4.7.1. Therapeutics
4.7.2. Epidemiology
4.7.3. Symptoms
4.7.4. Etiology
4.7.5. Pathophysiology
4.7.6. Diagnosis
4.8. Global Guillain–Barré Syndrome Market: Key Mergers & Acquisitions
4.9. Guillain–Barré Syndrome: Pipeline Analysis
4.10. Guillain–Barré Syndrome: Major Research Institutes Involved
5. Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunity Analysis
5.4. Opportunities
6. Guillain–Barré Syndrome Market Analysis, by Therapeutics
6.1. Introduction
6.2. Global Guillain–Barré Syndrome Market Value Share Analysis, by Therapeutics
6.3. Guillain–Barré Syndrome Market Analysis, by Therapeutics
6.3.1. Intravenous Immunoglobulin
6.3.2. Plasma Exchange
6.3.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
6.4. Guillain–Barré Syndrome Market Attractiveness Analysis, by Therapeutics
7. Guillain–Barré Syndrome Market Analysis, by Route of Administration
7.1. Introduction
7.2. Global Guillain–Barré Syndrome Market Value Share Analysis, by Route of Administration
7.3. Guillain–Barré Syndrome Market Analysis, by Route of Administration
7.3.1. Oral
7.3.2. Parenteral
7.4. Guillain–Barré Syndrome Market Attractiveness Analysis, by Route of Administration
8. Guillain–Barré Syndrome Market Analysis, by Distribution Channel
8.1. Introduction
8.2. Global Guillain–Barré Syndrome Market Value Share Analysis, by Distribution Channel
8.3. Guillain–Barré Syndrome Market Analysis, by Distribution Channel
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Others (Home Care, Clinics, etc.)
8.4. Guillain–Barré Syndrome Market Attractiveness Analysis, by Distribution Channel
9. Guillain–Barré Syndrome Market Analysis, by Region
9.1. Global Guillain–Barré Syndrome Market Snapshot, by Country
9.2. Global Guillain–Barré Syndrome Market Value Share Analysis, by Region
9.3. Global Guillain–Barré Syndrome Market Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Rest of World
9.4. Global Guillain–Barré Syndrome Market Attractiveness Analysis, by Region
9.5. Key Market Trends, by Region
10. North America Guillain–Barré Syndrome Market Analysis
10.1. Key Findings
10.2. North America Guillain–Barré Syndrome Market Overview
10.3. North America Guillain–Barré Syndrome Market Value Share Analysis, by Therapeutics
10.4. North America Guillain–Barré Syndrome Market Forecast, by Therapeutics
10.4.1. Intravenous Immunoglobulin
10.4.2. Plasma Exchange
10.4.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
10.5. North America Guillain–Barré Syndrome Market Value Share Analysis, by Route of Administration
10.6. North America Guillain–Barré Syndrome Market Forecast, by Route of Administration
10.6.1. Oral
10.6.2. Parenteral
10.7. North America Guillain–Barré Syndrome Market Value Share Analysis, by Distribution Channel
10.8. North America Guillain–Barré Syndrome Market Forecast, by Distribution Channel
10.8.1. Hospital Pharmacies
10.8.2. Retail Pharmacies
10.8.3. Others (Home Care, Clinics, etc.)
10.9. North America Guillain–Barré Syndrome Market Analysis, by Country
10.10. North America Guillain–Barré Syndrome Market Value Share Analysis, by Country
10.11. North America Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Country, 2017–2025
10.11.1. U.S.
10.11.2. Canada
10.12. North America Guillain–Barré Syndrome Market Attractiveness Analysis
10.12.1. By Therapeutics
10.12.2. By Route of Administration
10.12.3. By Distribution Channel
10.12.4. By Country
11. Europe Guillain–Barré Syndrome Market Analysis
11.1. Key Findings
11.2. Europe Guillain–Barré Syndrome Market Overview
11.3. Europe Guillain–Barré Syndrome Market Value Share Analysis, by Therapeutics
11.4. Europe Guillain–Barré Syndrome Market Forecast, by Therapeutics
11.4.1. Intravenous Immunoglobulin
11.4.2. Plasma Exchange
11.4.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
11.5. Europe Guillain–Barré Syndrome Market Value Share Analysis, by Route of Administration
11.6. Europe Guillain–Barré Syndrome Market Forecast, by Route of Administration
11.6.1. Oral
11.6.2. Parenteral
11.7. Europe Guillain–Barré Syndrome Market Value Share Analysis, by Distribution Channel
11.8. Europe Guillain–Barré Syndrome Market Forecast, by Distribution Channel
11.8.1. Hospital Pharmacies
11.8.2. Retail Pharmacies
11.8.3. Others (Home Care, Clinics, etc.)
11.9. Europe Guillain–Barré Syndrome Market Analysis, by Country/Sub-region
11.10. Europe Guillain–Barré Syndrome Market Value Share Analysis, by Country/Sub-region
11.11. Europe Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2025
11.11.1. U.K.
11.11.2. Germany
11.11.3. Italy
11.11.4. France
11.11.5. Spain
11.11.6. Rest of Europe
11.12. Europe Guillain–Barré Syndrome Market Attractiveness Analysis
11.12.1. By Therapeutics
11.12.2. By Route of Administration
11.12.3. By Distribution Channel
11.12.4. By Country/Sub-region
12. Asia Pacific Guillain–Barré Syndrome Market Analysis
12.1. Key Findings
12.2. Asia Pacific Guillain–Barré Syndrome Market Overview
12.3. Asia Pacific Guillain–Barré Syndrome Market Value Share Analysis, by Therapeutics
12.4. Asia Pacific Guillain–Barré Syndrome Market Forecast, by Therapeutics
12.4.1. Intravenous Immunoglobulin
12.4.2. Plasma Exchange
12.4.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
12.5. Asia Pacific Guillain–Barré Syndrome Market Value Share Analysis, by Route of Administration
12.6. Asia Pacific Guillain–Barré Syndrome Market Forecast, by Route of Administration
12.6.1. Oral
12.6.2. Parenteral
12.7. Asia Pacific Guillain–Barré Syndrome Market Value Share Analysis, by Distribution Channel
12.8. Asia Pacific Guillain–Barré Syndrome Market Forecast, by Distribution Channel
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Others (Home Care, Clinics, etc.)
12.9. Asia Pacific Guillain–Barré Syndrome Market Analysis, by Country/Sub-region
12.10. Asia Pacific Guillain–Barré Syndrome Market Value Share Analysis, by Country/Sub-region
12.11. Asia Pacific Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2025
12.11.1. China
12.11.2. Japan
12.11.3. India
12.11.4. ASEAN
12.11.5. Rest of Asia Pacific
12.12. Asia Pacific Guillain–Barré Syndrome Market Attractiveness Analysis
12.12.1. By Therapeutics
12.12.2. By Route of Administration
12.12.3. By Distribution Channel
12.12.4. By Country/Sub-region
13. Rest of World Guillain–Barré Syndrome Market Analysis
13.1. Key Findings
13.2. Rest of World Guillain–Barré Syndrome Market Overview
13.3. Rest of World Guillain–Barré Syndrome Market Value Share Analysis, by Therapeutics
13.4. Rest of World Guillain–Barré Syndrome Market Forecast, by Therapeutics
13.4.1. Intravenous Immunoglobulin
13.4.2. Plasma Exchange
13.4.3. Others (Analgesics, Anticonvulsants, LMWH, etc.)
13.5. Rest of World Guillain–Barré Syndrome Market Value Share Analysis, by Route of Administration
13.6. Rest of World Guillain–Barré Syndrome Market Forecast, by Route of Administration
13.6.1. Oral
13.6.2. Parenteral
13.7. Rest of World Guillain–Barré Syndrome Market Value Share Analysis, by Distribution Channel
13.8. Rest of World Guillain–Barré Syndrome Market Forecast, by Distribution Channel
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Others (Home Care, Clinics, etc.)
13.9. Rest of World Guillain–Barré Syndrome Market Attractiveness Analysis
13.9.1. By Therapeutics
13.9.2. By Route of Administration
13.9.3. By Distribution Channel
14. Company Profiles
14.1. Global Guillain–Barré Syndrome Market Share Analysis, by Company, 2016
14.2. Competition Matrix
14.3. Company Profiles
14.3.1. Grifols S.A.
14.3.1.1. Company Details
14.3.1.2. Business Overview
14.3.1.3. Strategic Overview
14.3.1.4. SWOT Analysis
14.3.2. CSL Behring LLC
14.3.2.1. Company Details
14.3.2.2. Business Overview
14.3.2.3. Strategic Overview
14.3.2.4. SWOT Analysis
14.3.3. Shire plc
14.3.3.1. Company Details
14.3.3.2. Business Overview
14.3.3.3. Strategic Overview
14.3.3.4. SWOT Analysis
14.3.4. Octapharma AG
14.3.4.1. Company Details
14.3.4.2. Business Overview
14.3.4.3. Strategic Overview
14.3.4.4. SWOT Analysis
14.3.5. Nihon Pharmaceutical Co., Ltd.
14.3.5.1. Company Details
14.3.5.2. Business Overview
14.3.5.3. Strategic Overview
14.3.5.4. SWOT Analysis
14.3.6. Akari Therapeutics, PLC
14.3.6.1. Company Details
14.3.6.2. Business Overview
14.3.6.3. Strategic Overview
14.3.6.4. SWOT Analysis
14.3.7. China Biologic Products Holdings, Inc.
14.3.7.1. Company Details
14.3.7.2. Business Overview
14.3.7.3. Strategic Overview
14.3.7.4. SWOT Analysis
14.3.8. Biotest AG
14.3.8.1. Company Details
14.3.8.2. Business Overview
14.3.8.3. Strategic Overview
14.3.8.4. SWOT Analysis
14.3.9. Kedrion s.p.A.
14.3.9.1. Company Details
14.3.9.2. Business Overview
14.3.9.3. Strategic Overview
14.3.9.4. SWOT Analysis
List of Tables
TABLE 1 Global Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015–2025
TABLE 2 Global Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
TABLE 3 Global Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
TABLE 4 Global Guillain–Barré Syndrome Market Value (US$ Mn) Forecast, by Region, 2015–2025
TABLE 5 North America Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Country, 2015–2025
TABLE 6 North America Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015–2025
TABLE 7 North America Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
TABLE 8 North America Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
TABLE 9 Europe Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
TABLE 10 Europe Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015–2025
TABLE 11 Europe Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
TABLE 12 Europe Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
TABLE 13 Asia Pacific Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
TABLE 14 Asia Pacific Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015–2025
TABLE 15 Asia Pacific Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
TABLE 16 Asia Pacific Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
TABLE 17 Rest of World Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Therapeutics, 2015–2025
TABLE 18 Rest of World Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
TABLE 19 Rest of World Guillain–Barré Syndrome Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
List of Figures
Figure 01: Global Guillain–Barré Syndrome Market Snapshot
Figure 02: Global Guillain–Barré Syndrome Market Size (US$ Mn) and Distribution, by Region, 2017 and 2025
Figure 03: Global Guillain–Barré Syndrome Market Opportunity Map, 2016
Figure 04: Global Guillain–Barré Syndrome Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2015–2025
Figure 05: Guillain–Barré Syndrome Market Value Share, by Therapeutics (2016)
Figure 06: Guillain–Barré Syndrome Market Value Share, by Route of Administration (2016)
Figure 07: Guillain–Barré Syndrome Market Value Share, by Distribution Channel (2016)
Figure 08: Key Industry Developments
Figure 09: Key Market Developments
Figure 10: Porter’s Five Forces
Figure 11: Key Success Factors of Top 3 Players
Figure 12: Global Guillain–Barré Syndrome Market Value Share, by Therapeutics, 2017 and 2025
Figure 13: Global Guillain–Barré Syndrome Market Revenue (US$ Mn) Forecast, by Intravenous Immunoglobulin, 2015–2025
Figure 14: Global Guillain–Barré Syndrome Market Revenue (US$ Mn) Forecast, by Plasma Exchange, 2015–2025
Figure 15: Global Guillain–Barré Syndrome Market Revenue (US$ Mn) Forecast, by Others, 2015–2025
Figure 16: Global Guillain–Barré Syndrome Market Attractiveness Analysis, by Therapeutics, 2017–2025
Figure 17: Global Guillain–Barré Syndrome Market Value Share, by Route of Administration, 2017 and 2025
Figure 18: Global Guillain–Barré Syndrome Market Revenue (US$ Mn) Forecast, by Oral, 2015–2025
Figure 19: Global Guillain–Barré Syndrome Market Revenue (US$ Mn) Forecast, by Parenteral, 2015–2025
Figure 20: Global Guillain–Barré Syndrome Market Attractiveness Analysis, by Route of Administration, 2017–2025
Figure 21: Global Guillain–Barré Syndrome Market Value Share, by Distribution Channel, 2017 and 2025
Figure 22: Global Guillain–Barré Syndrome Market Revenue (US$ Mn) Forecast, by Hospital Pharmacies, 2015–2025
Figure 23: Global Guillain–Barré Syndrome Market Revenue (US$ Mn) Forecast, by Retail Pharmacies, 2015–2025
Figure 24: Global Guillain–Barré Syndrome Market Revenue (US$ Mn) Forecast, by Others, 2015–2025
Figure 25: Global Guillain–Barré Syndrome Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 26: Global Guillain–Barré Syndrome Market Value Share, by Region, 2017 and 2025
Figure 27: Global Guillain–Barré Syndrome Market Attractiveness, by Region, 2017–2025
Figure 28: North America Guillain–Barré Syndrome Market Value (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 29: North America Guillain–Barré Syndrome Market Value Share, by Country, 2017 and 2025
Figure 30: North America Guillain–Barré Syndrome Market Value Share, by Therapeutics, 2017 and 2025
Figure 31: North America Guillain–Barré Syndrome Market Value Share, by Route of Administration, 2017 and 2025
Figure 32: North America Guillain–Barré Syndrome Market Value Share, by Distribution Channel, 2017 and 2025
Figure 33: North America Guillain–Barré Syndrome Market Attractiveness Analysis, by Therapeutics, 2017–2025
Figure 34: North America Guillain–Barré Syndrome Market Attractiveness Analysis, by Route of Administration, 2017–2025
Figure 35: North America Guillain–Barré Syndrome Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 36: North America Guillain–Barré Syndrome Market Attractiveness Analysis, by Country, 2017–2025
Figure 37: Europe Guillain–Barré Syndrome Market Value (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 38: Europe Guillain–Barré Syndrome Market Value Share, by Country/Sub-region, 2017 and 2025
Figure 39: Europe Guillain–Barré Syndrome Market Value Share, by Therapeutics, 2017 and 2025
Figure 40: Europe Guillain–Barré Syndrome Market Value Share, by Route of Administration, 2017 and 2025
Figure 41: Europe Guillain–Barré Syndrome Market Value Share, by Distribution Channel, 2017 and 2025
Figure 42: Europe Guillain–Barré Syndrome Market Attractiveness Analysis, by Therapeutics, 2017–2025
Figure 43: Europe Guillain–Barré Syndrome Market Attractiveness Analysis, by Route of Administration, 2017–2025
Figure 44: Europe Guillain–Barré Syndrome Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 45: Europe Guillain–Barré Syndrome Market Attractiveness Analysis, by Country/Sub-region, 2017–2025
Figure 46: Asia Pacific Guillain–Barré Syndrome Market Value (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 47: Asia Pacific Guillain–Barré Syndrome Market Value Share, by Country/Sub-region, 2017 and 2025
Figure 48: Asia Pacific Guillain–Barré Syndrome Market Value Share, by Therapeutics, 2017 and 2025
Figure 49: Asia Pacific Guillain–Barré Syndrome Market Value Share, by Route of Administration, 2017 and 2025
Figure 50: Asia Pacific Guillain–Barré Syndrome Market Value Share, by Distribution Channel, 2017 and 2025
Figure 51: Asia Pacific Guillain–Barré Syndrome Market Attractiveness, by Therapeutics, 2017–2025
Figure 52: Asia Pacific Guillain–Barré Syndrome Market Attractiveness, by Route of Administration, 2017–2025
Figure 53: Asia Pacific Guillain–Barré Syndrome Market Attractiveness, by Distribution Channel, 2017–2025
Figure 54: Asia Pacific Guillain–Barré Syndrome Market Attractiveness, by Country/Sub-region, 2017–2025
Figure 55: Rest of World Guillain–Barré Syndrome Market Value (US$ Mn) and Y-o-Y Growth (%), 2015–2025
Figure 56: Rest of World Guillain–Barré Syndrome Market Value Share, by Therapeutics, 2017 and 2025
Figure 57: Rest of World Guillain–Barré Syndrome Market Value Share, by Route of Administration, 2017 and 2025
Figure 58: Rest of World Guillain–Barré Syndrome Market Value Share, by Distribution Channel, 2017 and 2025
Figure 59: Rest of World Guillain–Barré Syndrome Market Attractiveness, by Therapeutics, 2017–2025
Figure 60: Rest of World Guillain–Barré Syndrome Market Attractiveness, by Route of Administration, 2017–2025
Figure 61: Rest of World Guillain–Barré Syndrome Market Attractiveness, by Distribution Channel, 2017–2025
Figure 62: Global Guillain–Barré Syndrome Market Share Analysis, by Company (2016)
Figure 63: Shire plc Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 64: Shire plc Breakdown of Net Sales (%), by Business Segment, 2017
Figure 65: Shire plc Breakdown of Net Sales (%), by Geography, 2017
Figure 66: CSL Behring LLC Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 67: CSL Behring LLC Breakdown of Net Sales (%), by Business Segment, 2017
Figure 68: CSL Behring LLC Breakdown of Net Sales (%), by Geography, 2016
Figure 69: Grifols, S.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 70: Grifols, S.A. Breakdown of Net Sales (%), by Business Segment, 2017
Figure 71: Grifols, S.A. Breakdown of Net Sales (%), by Region, 2016
Figure 72: Octapharma AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 73: Octapharma AG: R&D Expenses (US$ Mn), 2014–2017
Figure 74: Nihon Pharmaceutical Co., Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 75: Takeda Pharmaceutical Company Limited Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 76: Takeda Pharmaceutical Company Limited Breakdown of Ethical Drugs: Revenue (%), by Region, 2016
Figure 77: China Biologic Products Holdings, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 78: China Biologic Products Holdings, Inc. Breakdown of Net Sales (%), by Business Segment, 2017
Figure 79: Biotest AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 80: Biotest AG Breakdown of Net Sales (%), by Region, 2016
Figure 81: Biotest AG Breakdown of Net Sales (%), by Business Segment, 2016
Figure 82: Kedrion S.p.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 83: Kedrion S.p.A. Breakdown of Net Sales (%), by Region, 2016
Figure 84: Kedrion S.p.A. Breakdown of Net Sales (%), by Business Segment, 2016
